First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia

Leukemia

Volumn 26, Issue 10, 2012, Pages 2254-2259

  Rea, D ^a,o   Etienne, G ^b,o   Nicolini, F ^c,o   Cony Makhoul, P ^d,o   Johnson Ansah, H ^e,o   Legros, L ^f,o   Huguet, F ^g,o   Tulliez, M ^h,o   Gardembas, M ^i,o   Bouabdallah, K ^j,o   Rousselot, P ^k,o   Cayuela, J M ^l,o   Guilhot, F ^m,o   Mahon, F X ^n,o  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT BERGONIÉ   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d Service d'Hématologie clinique HÔpital Saint Antoine   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g CHU PURPAN   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j HAUT LÉVÊQUE HOSPITAL   (France)

^k CENTRE HOSPITALIER DE VERSAILLES   (France)

^l Laboratoire Central d'Hematologie   (France)

^m POITIERS UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o France Intergroupe Leucémie Myéloïde Chronique FI LMC   (France)

more..

Author keywords

Accelerated phase; Chronic myeloid leukemia; Frontline imatinib

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FAILURE FREE SURVIVAL; FEMALE; HUMAN; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

EID: 84867397243     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.92     Document Type: Article

References (22)

1. Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F et al. Prognostic significance of additional chromosomal abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294-298.
2. Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 2004; 4: 85-96. (Pubitemid 38208489)
3. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. New Engl J Med 1999; 341: 164-172. (Pubitemid 29325745)
4. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937. (Pubitemid 34525471)
5. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Vertovsek S et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer 2005; 103: 2099-2108. (Pubitemid 40605118)
6. Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukaemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 2009; 94: 743-744.
7. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations of an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820. (Pubitemid 44394987)
8. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
9. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446. (Pubitemid 18076421)
10. Cortes J, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A et al. Staging of chronic myeloid leukemia in the imatinib era. Cancer 2006; 106: 1306-1315.
11. Shaffer LG, Slovac ML, Campbell LJ. (eds). ISCN 2009: An International System for Human Cytogenetic Nomenclature. Karge AG: Basel, Switzerland, 2009.
12. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J et al. Treatment of Philadelphia chromosome-positive accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167-2176. (Pubitemid 34753587)
13. Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S et al. The longterm durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after 7-year follow-up. Haematologica 2008; 94: 205-212.
14. Hochhaus H, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al. Favorable long-term follow-up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-a treatment. Blood 2008; 111: 1039-1043. (Pubitemid 351213381)
15. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417. (Pubitemid 44903745)
16. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760-6768.
17. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S et al. The impact of clonal evolution on the response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100: 1628-1633. (Pubitemid 34925138)
18. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J et al. Prognostic significance of clonal cytogenetic evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794-3800. (Pubitemid 36857848)
19. Apperley JF, Cortes JE, Kim D-W, Roy L, Roboz GJ, Rosti G et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009; 27: 3472-3479.
20. Le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834-1839. (Pubitemid 351451490)
21. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2010; 362: 2260-2270.
22. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2010; 362: 2251-2259.